Cabiralizumab (FPA008, Five Prime Therapeutics) completed Phase 1/2 trials to evaluate the safety, tolerability, and effectiveness of Cabiralizumab in diffuse TGCT.
While both Vimseltinib and Pexidartinib are molecule-based drugs (like many oral pills on market), this drug relies on a protein antibody that blocks CSF1 by holding onto it and preventing it from reaching TGCT and surrounding cells. This drug was given as an intravenous infusion for 30 minutes every 2-to-4 weeks.
By blocking CSF1, the tumor cannot grow and develop. This clinical trial took place at 12 different global clinical locations.
For more information, visit the clinical trial website for Cabiralizumab or ask your healthcare provider. As of 2021, Amgen has acquired this company. It is unknown whether this drug will continue.
